Shots:
RQ Bio to receive up front & milestones of ~$157M along with royalties. The agreement was supported through continued collaborations with the University of Oxford & LifeArc
AstraZeneca gets an exclusive license globally for RQ Bio’s early-stage mAbs against SARS-CoV-2 & obtains the right to exclusively license an additional mAbs against SARS-CoV-2. The collaboration combines RQ Bio’s expertise to develop neutralizing Ab therapy for SARS-CoV-2 & for other viral inf. diseases
RQ Bio continues to develop treatments & preventative therapies, based on broad-spectrum mAbs that give immediate & long-lasting immunity to patients who are at risk of serious disease or death from viral inf.
Ref: PRNewswire | Image: AstraZeneca
